Loss of heterozygosity at D14S62 and metastatic potential of breast cancer

O'Connell, Peter; Fischbach, Kathryn; O'Connell, P; Fischbach, K; Hilsenbeck, S; Mohsin, S K; Fuqua, S A; Clark, G M; Osborne, C K; Allred, D C
August 1999
JNCI: Journal of the National Cancer Institute;08/18/99, Vol. 91 Issue 16, p1391
Academic Journal
journal article
Background: In breast cancer progression, the prevalence of damage at specific genetic loci often increases with the stage of the lesion (i.e., from noninvasive to invasive to metastatic). By use of genetic markers and analysis of allelic imbalances (loss of heterozygosity [LOH]) to compare DNA samples from paired normal and breast tumor tissues, we examined whether specific genetic changes in primary breast cancers can serve as biomarkers of metastatic potential.Methods: DNA samples from 76 patients with primary breast cancer (42 with axillary lymph node-negative disease and 34 with axillary lymph node-positive disease) were genotyped with four genetic markers spanning chromosome 14q31-q32. The intensity ratios of the two genetic alleles in normal-tumor DNA pairs were examined in genetically informative individuals. LOH was scored when the tumor allele intensity ratio (tumor allele 1/tumor allele 2) divided by the normal allele intensity ratio (normal allele 1/normal allele 2) was either less than 0.71 (tumor allele 1 LOH) or greater than 1. 4 (tumor allele 2 LOH).Results/conclusions: Contrary to our expectations, we found statistically significantly more LOH events at markers D14S62 (two-sided P =.001) and D14S51 (two-sided P =.02) in primary breast cancers from patients with lymph node-negative disease versus lymph node-positive disease, suggesting the presence of a gene in this region that affects metastatic potential. Analysis of small interstitial or terminal deletions in the tumors of six especially informative patients with lymph node-negative disease places the putative metastasis-related gene in a 1490-kilobase region near D14S62.Implications: LOH in the D14S62 region may impede the process of metastasis. Therefore, the D14S62 region LOH profile may have prognostic implications, and the isolation of the metastasis-related gene(s) in this region may lead to better diagnosis and treatment of breast cancer.


Related Articles

  • Reply. Gommans, M.; van Dongen, A.; Boer, O. // European Journal of Nuclear Medicine & Molecular Imaging;2002, Vol. 29 Issue 6, p832 

    Presents a reply to a correspondence on use of technetium isotopes to label colloid albumin molecules that will enable the identification of sentinel lymph nodes in breast cancer. Influence of the age and extent of tumor invasive in the count rate of sentinel lymph nodes; Correlation of...

  • Methodology of [sup 99m] Tc-Nanocoll sentinel node localisation in carcinoma of the breast. Bourgeois, P.; Leduc, O.; Belgrado, P.; Leduc, A. // European Journal of Nuclear Medicine & Molecular Imaging;2002, Vol. 29 Issue 6, p831 

    Presents correspondence on use of technetium isotopes to label colloid albumin molecules that will enable the identification of sentinel lymph nodes in breast cancer. Comparison of lymph node activity produced using intradermal mode of injection versus subcutaneous injection; Influence of...

  • BIOMARKER BEGINS PILOT STUDY OF BREAST CANCER BLOOD TEST.  // Biotech Business;May2005, Vol. 18 Issue 5, p5 

    Reports that Biomarker Technologies LLC has begun a pilot study of the BT Test, a blood diagnostic test for the detection of breast cancer, in the U.S. Key reason for the conduscting the pilot study; Statement of Biomarker CEO William Gartner about BT Test; Number of women diagnosed with breast...

  • miRNA as Potential Biomarkers of Breast Cancer in the Lebanese Population and in Young Women: A Pilot Study. Nassar, Farah J.; El Sabban, Maya; Zgheib, Nathalie K.; Tfayli, Arafat; Boulos, Fouad; Jabbour, Mark; Saghir, Nagi S. E. l.; Talhouk, Rabih; Bazarbachi, Ali; Calin, George A.; Nasr, Rihab // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Relative to western populations, the percentage of women diagnosed with breast cancer at a young age in Lebanon is high. While the younger age of the Lebanese population compared to the West certainly contributes to this difference, potential genetic, reproductive and/or biological factors...

  • King touts Broca test's ability to detect breast, ovarian cancer. FORD, OMAR // Medical Device Daily;7/26/2011, Vol. 15 Issue 138, p1 

    The article reports on the American Association for Clinical Chemistry annual meeting held in Atlanta, Georgia in July 2011. The highlight of the start of the annual meeting was a presentation by U.S. human geneticist Mary-Claire King on a technique she developed to diagnose breast cancer. King...

  • University of North Dakota Signs License to Develop Breast Cancer Detection Technology with NeoMatrix LLC, Makers of the Halo(r) Pap Test.  // Biomedical Market Newsletter;1/14/2012, Vol. 21, p1 

    The article presents information on an exclusive option agreement made by University of North Dakota, North Dakota with NeoMatrix LLC in order to develop the HALO(r) breast assay for the early detection of breast cancer. It discusses the use of this assay in screening and assessing breast cancer...

  • Prognostic Significance of Deregulated Dicer Expression in Breast Cancer. Caffrey, Emer; Ingoldsby, Helen; Wall, Deirdre; Webber, Mark; Dinneen, Kate; Murillo, Laura S.; Inderhaug, Celine; Newell, John; Gupta, Sanjeev; Callagy, Grace // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Background: Dicer, an RNase III-type endonuclease, is the key enzyme involved in RNA interference and microRNA pathways. Aberrant expression of Dicer is reported in several human cancers. Our aim was to assess the prognostic role of Dicer in breast cancer. Methods: The entire series comprised...

  • Nanoelectronic detection of breast cancer biomarker. Chen, Yu; Wang, Xihua; Hong, Mi K.; Rosenberg, Carol L.; Reinhard, Bj√∂rn M.; Erramilli, Shyamsunder; Mohanty, Pritiraj // Applied Physics Letters;12/6/2010, Vol. 97 Issue 23, p233702 

    There is a fundamental need for semiconductor-based ultrasensitive nanosensors for detecting heterogeneous biomarkers associated with cancer, which do not have a well-defined molecular weight. Here we show that a nanoscale gated biological field effect transistor can be used for detecting the...

  • A Novel Color Change Mechanism for Breast Cancer Biomarker Detection: Naphthoquinones as Specific Ligands of Human Arylamine N-Acetyltransferase 1. Laurieri, Nicola; Egleton, James E.; Varney, Amy; Thinnes, Cyrille C.; Quevedo, Camilo E.; Seden, Peter T.; Thompson, Sam; Rodrigues-Lima, Fernando; Dairou, Julien; Dupret, Jean-Marie; Russell, Angela J.; Sim, Edith // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Human arylamine N-acetyltransferase 1 (hNAT1) has become an attractive potential biomarker for estrogen-receptor-positive breast cancers. We describe here the mechanism of action of a selective non-covalent colorimetric biosensor for the recognition of hNAT1 and its murine homologue, mNat2, over...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics